From: aacr.org Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with newly diagnosed human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has either metastasized or cannot be removed with surgery. Concurrently, two tests …
Triple negative breast cancer cells use new strategy to boost metastatic ability
Source: Baylor College of Medicine From: news-medical.net Researchers at Baylor College of Medicine have uncovered a strategy that triple negative breast cancer (TNBC) cells use to boost their ability to metastasize, or spread to other organs. Metastasis is the leading cause of cancer-related deaths and scientists are investigating ways to prevent it. These findings, published in Nature Communications, highlight new …
Living with Breast Cancer: Understanding the Physical and Mental Changes
From: healthline.com Key Takeaways Breast cancer treatments can cause menstrual changes, hair loss, swelling, skin changes, and weight gain, but many of these side effects are temporary and manageable with proper care. Mental health support, such as therapy and self-care practices, is crucial during breast cancer treatment due to the common occurrence of depression and anxiety. Strategies can help manage …
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
By: Sabrina Serani From: targetedonc.com Key Takeaways CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising results, with a 56% objective response rate and 7.4 months median progression-free survival. The CD47-SIRPα pathway blockade by evorpacept enhances macrophage-mediated phagocytosis, potentially amplifying HER2-targeted therapy effects. Future research will …
Purdue researchers discover new therapeutic target for triple-negative breast cancer
Source: Purdue University From: news-medical.net A Purdue University team led by Kyle Cottrell has discovered a new therapeutic target for triple-negative breast cancer. Cottrell, biochemistry graduate student Addison Young and their co-authors describe the discovery in the journal RNA. The laboratory research spotlights double-stranded ribonucleic acid (dsRNA)-binding proteins. “Generally, people are taught in high school biology that RNA is single-stranded. …
Palbociclib improves progression-free survival in HER2 positive breast cancer
Source: PrECOG, LLC From: news-medical.net PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England Journal of Medicine (NEJM). The study evaluated whether adding palbociclib to anti-HER2 and endocrine therapy, following induction chemotherapy, could delay disease progression in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) metastatic …
This Common Bacterium Hiding in Your Mouth May Help Trigger Breast Cancer
By: Johns Hopkins From; scitechdaily.com A bacterium best known for causing gum disease may also influence how breast cancer begins and spreads. A team at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy reports that a mouth-dwelling bacterium tied to periodontal disease could help set breast cancer in motion and make it more aggressive. In …
AI-supported mammography screening results in fewer aggressive and advanced breast cancers
By: Lancet From: medicalxpress.com Artificial intelligence (AI)-supported mammography identifies more cancers during screening and reduces the rate of breast cancer diagnosis by 12% in the years following, finds the first randomized controlled trial of its kind. The trial involved over 100,000 Swedish women, and its results are published in The Lancet. The interim safety results of the MASAI trial, published …
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
By: Sabrina Serani From: targetedonc.com Key Takeaways Multiomic profiling, including whole exome and transcriptome sequencing, offers prognostic value beyond standard HER2 immunohistochemistry. HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. Elevated ABCC1 expression is associated with poorer outcomes, indicating its role in resistance to T-DXd. Integrating multiomic data into clinical practice …
Testing risk-based breast cancer screening
By: Yolanda L. Jones, MS, MBA From: nih.gov Breast cancer is the second most common type of cancer among women in the United States and is the second leading cause of cancer death. Recommendations for breast cancer screening have generally been based on age rather than an individual’s risk for the disease. Risk can vary significantly depending on a person’s …